ClinicalTrials.gg
Active, not recruitingNCT04903288Updated Apr 24, 2026Results posted

A Study of SmartFlow Magnetic Resonance (MR) Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric Participants

A Phase 2 interventional study of Eladocagene Exuparvovec in AADC Deficiency, sponsored by PTC Therapeutics. Active, not recruiting at 6 sites in 3 countries. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2026-04-24.

Sponsored by PTC Therapeutics · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
1 Year to 17 Years
Sex
All
01

Study summary

This study will have a trial phase, extension phase, and a long-term extension phase. The primary objectives of the trial phase are to assess the pharmacodynamics (PD) of eladocagene exuparvovec treatment by evaluation of homovanillic acid (HVA) levels and to assess the safety of the SmartFlow® magnetic resonance (MR) Compatible Ventricular Cannula for administering eladocagene exuparvovec to pediatric participants with aromatic L-amino acid decarboxylase (AADC) deficiency. The extension phase is designed to capture additional clinical information for eladocagene exuparvovec through study evaluations, changes in motor development, AADC-specific symptoms, and other PD measures. The long-term extension phase is designed to capture long-term safety and efficacy data from participants treated with eladocagene exuparvovec.

02

Conditions studied

  • AADC Deficiency

Keywords

  • AADC Deficiency gene therapy
03

In context

Lead sponsor

PTC Therapeutics is the lead sponsor of 65 studies on the registry; 3 are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 14 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pediatric participants must have genetically-confirmed AADC deficiency with typical clinical characteristics and decreased AADC enzyme activity in plasma.
  • Cranium sufficiently developed to allow placement of ClearPoint® system for stereotactic surgery.
  • Persistent neurological defects secondary to AADC deficiency despite standard medical therapy (dopamine agonists, monoamine oxidase inhibitor, pyridoxine, or other forms of vitamin B6) in the opinion of the investigator.
  • Unable to ambulate independently (with or without assistive device).
  • Baseline hematology, chemistry, and coagulation values within the normal pediatric laboratory value ranges, unless in the investigator's opinion the out of range values are not with respect to the participant's suitability for surgery.
  • Participant must test negative for coronavirus disease of 2019 (COVID-19) a maximum of 72 hours prior to receiving gene therapy.
  • Participant must be on stable dosage for 3 months prior to baseline for all medications related to treatment of AADC deficiency, including dopamine agonists, monoamine oxidase inhibitors, anticholinergic drugs, and vitamin B6.
  • Females of must have a negative pregnancy test at screening and baseline and agree to abstinence or double-barrier form of for the duration of the study following discharge from the hospital (acceptable methods will be determined by the site).
  • Males sexually active with females of childbearing potential must agree to use a barrier method of birth control during the study following discharge from the hospital.
  • Parent(s)/legal guardian(s) of the participant must agree to comply with the requirements of the study, including the need for frequent and prolonged follow up.
  • Parent(s)/legal guardian(s) with custody of the participant must give their consent for the participant to enroll in the study.

Exclusion criteria

Exclusion Criteria:

  • The participant has presence of other significant medical or neurological conditions that would create an unacceptable operative or anesthetic risk.
  • Participants with pyridoxine 5'-phosphate oxidase or tetrahydrobiopterin (BH4) deficiency.
  • for imaging studies (computed tomography [CT] scan, PET or magnetic resonance imaging [MRI]), including sedation limitations or metal that would interfere with a brain MRI.
  • Anti-adeno-associated virus, serotype 2 (anti-AAV2) antibody titer higher than 1:1200 or >1 optical density value by enzyme-linked immunosorbent assay.
  • Participants who have received treatment with other experimental therapies within the last 24 weeks prior to planned gene therapy administration, or any treatment ever with a gene therapy.
  • Evidence of a clinically active infection.
  • Females who are pregnant or breast feeding.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Eladocagene Exuparvovec

    Participants will receive eladocagene exuparvovec intraoperatively at 1.8×10\^11 vector genomes (vg) via SmartFlow® MR Compatible Ventricular Cannula in a single operative session. Participants will receive standard of care for their AADC deficiency during the study.

    Genetic: Eladocagene Exuparvovec

Interventions

  • GeneticEladocagene Exuparvovec

    Four 0.08 milliliters (mL) infusions at a dose of 0.45×10\^11 vg and a volume of 80 microliters (μl) per site to 4 sites (2 per putamen), for the total dose of 1.8×10\^11 vg and a total volume of 320 μl per participant.

    Also known as: KEBILIDI™

06

What researchers measure

Primary outcomes

  1. Change From Baseline in HVA Metabolite Level at the End of the Trial Phase

    HVA is a main metabolite of dopamine and HVA CSF levels are recognized as a proxy for dopamine levels in the brain.

    Time frame: Baseline (Day 1), Week 8

  2. Number of Participants With Adverse Events (AEs) Associated With the Surgical Administration of Eladocagene Exuparvovec Using the SmartFlow® MR-Compatible Ventricular Cannula

    An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered related to the drug. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease in a study participant who was administered gene therapy in this study. Number of participants with AEs related to the SmartFlow MR-compatible ventricular cannula used to administer eladocagene exuparvovec to pediatric participants at the end of Trial Phase (8 weeks after administration) are reported. A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module."

    Time frame: Baseline (Day 1) up to Week 8

Secondary outcomes

  1. Change From Baseline in Neurotransmitter Cerebrospinal Fluid (CSF) Metabolite HVA at Week 48

    Time frame: Baseline (Day 1), Week 48

  2. Change From Baseline in Positron Emission Tomography (PET) Imaging of Putaminal-Specific L-6-[18F] Fluoro-3,4-Dihydroxyphenylalnine (18F-DOPA) PET Uptake at the End of the Trial Phase (Week 8) and the Extension Phase (Week 48)

    Time frame: Baseline (Day 1), Week 8, Week 48

  3. Change From Baseline in Neurotransmitter CSF Metabolites 5-hydroxyindoleacetic Acid (5-HIAA), and 3-O-methyldopa (3-OMD) at Weeks 8 and 48

    Time frame: Baseline (Day 1), Weeks 8 and 48

  4. Number of Participants Who Attain Motor Milestones

    Time frame: Baseline (Day 1) up to Week 260

  5. Change in Peabody Developmental Motor Scale, Second Edition (PDMS-2)

    Time frame: Baseline (Day 1), Week 260

  6. Change in Bayley Scale of Infant Development, Third Edition (Bayley-III)

    Time frame: Baseline (Day 1), Week 260

  7. Change in EuroQol-5 Dimensions Youth Version (EQ-5D-Y)

    Time frame: Baseline (Day 1), Week 260

  8. Change in Body Weight

    Time frame: Baseline (Day 1), Week 260

  9. Number of Participants With AADC-Specific Symptoms

    Time frame: Baseline (Day 1) up to Week 260

  10. "Number of Participants With Treatment-Emergent Adverse Events (TEAEs) "

    Time frame: Baseline (Day 1) up to Week 260

07

Results

Posted Jan 1, 2025

Participant flow

Trial Phase (8 Weeks)
Participant flow — Trial Phase (8 Weeks)
MilestoneEladocagene Exuparvovec
Started13
Received at least 1 dose of study drug13
Completed13
Not completed0
Extension Phase (48 Weeks)
Participant flow — Extension Phase (48 Weeks)
MilestoneEladocagene Exuparvovec
Started13
Completed9
Not completed4
Withdrew: Withdrawal by subject1
Withdrew: Ongoing in the study3
Long-Term Extension Phase (60 Months)
Participant flow — Long-Term Extension Phase (60 Months)
MilestoneEladocagene Exuparvovec
Started7
Completed0
Not completed7
Withdrew: Withdrawal by subject1
Withdrew: Ongoing in the study6

Outcome measures

PrimaryChange From Baseline in HVA Metabolite Level at the End of the Trial Phase

HVA is a main metabolite of dopamine and HVA CSF levels are recognized as a proxy for dopamine levels in the brain.

Time frame:
Baseline (Day 1), Week 8
Reported as:
Mean · nmol/L
Change From Baseline in HVA Metabolite Level at the End of the Trial Phase
nmol/LEladocagene Exuparvovec
Change From Baseline in HVA Metabolite Level at the End of the Trial Phase29.53 ± 12.93
PrimaryNumber of Participants With Adverse Events (AEs) Associated With the Surgical Administration of Eladocagene Exuparvovec Using the SmartFlow® MR-Compatible Ventricular Cannula

An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered related to the drug. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease in a study participant who was administered gene therapy in this study. Number of participants with AEs related to the SmartFlow MR-compatible ventricular cannula used to administer eladocagene exuparvovec to pediatric participants at the end of Trial Phase (8 weeks after administration) are reported. A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module."

Time frame:
Baseline (Day 1) up to Week 8
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) Associated With the Surgical Administration of Eladocagene Exuparvovec Using the SmartFlow® MR-Compatible Ventricular Cannula
ParticipantsEladocagene Exuparvovec
Number of Participants With Adverse Events (AEs) Associated With the Surgical Administration of Eladocagene Exuparvovec Using the SmartFlow® MR-Compatible Ventricular Cannula0
SecondaryChange From Baseline in Neurotransmitter Cerebrospinal Fluid (CSF) Metabolite HVA at Week 48
Time frame:
Baseline (Day 1), Week 48

Results for this outcome have not been posted.

SecondaryChange From Baseline in Positron Emission Tomography (PET) Imaging of Putaminal-Specific L-6-[18F] Fluoro-3,4-Dihydroxyphenylalnine (18F-DOPA) PET Uptake at the End of the Trial Phase (Week 8) and the Extension Phase (Week 48)
Time frame:
Baseline (Day 1), Week 8, Week 48

Results for this outcome have not been posted.

SecondaryChange From Baseline in Neurotransmitter CSF Metabolites 5-hydroxyindoleacetic Acid (5-HIAA), and 3-O-methyldopa (3-OMD) at Weeks 8 and 48
Time frame:
Baseline (Day 1), Weeks 8 and 48

Results for this outcome have not been posted.

SecondaryNumber of Participants Who Attain Motor Milestones
Time frame:
Baseline (Day 1) up to Week 260

Results for this outcome have not been posted.

SecondaryChange in Peabody Developmental Motor Scale, Second Edition (PDMS-2)
Time frame:
Baseline (Day 1), Week 260

Results for this outcome have not been posted.

SecondaryChange in Bayley Scale of Infant Development, Third Edition (Bayley-III)
Time frame:
Baseline (Day 1), Week 260

Results for this outcome have not been posted.

SecondaryChange in EuroQol-5 Dimensions Youth Version (EQ-5D-Y)
Time frame:
Baseline (Day 1), Week 260

Results for this outcome have not been posted.

SecondaryChange in Body Weight
Time frame:
Baseline (Day 1), Week 260

Results for this outcome have not been posted.

SecondaryNumber of Participants With AADC-Specific Symptoms
Time frame:
Baseline (Day 1) up to Week 260

Results for this outcome have not been posted.

Secondary"Number of Participants With Treatment-Emergent Adverse Events (TEAEs) "
Time frame:
Baseline (Day 1) up to Week 260

Results for this outcome have not been posted.

Adverse events

Collected over Baseline (Day 1) up to the interim data cut-off date (up to 897 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eladocagene Exuparvovec0/13 (0%)9/13 (69.2%)13/13 (100%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventEladocagene Exuparvovec
PneumoniaInfections and infestations3/13
BradycardiaCardiac disorders1/13
VomitingGastrointestinal disorders1/13
PyrexiaGeneral disorders1/13
Bacterial infectionInfections and infestations1/13
COVID-19Infections and infestations1/13
Metapneumovirus pneumoniaInfections and infestations1/13
Pneumonia viralInfections and infestations1/13
Urinary tract infectionInfections and infestations1/13
DyskinesiaNervous system disorders1/13
Most frequent other events
Showing 10 of 95
Most frequent other events
EventEladocagene Exuparvovec
PyrexiaGeneral disorders10/13
DyskinesiaNervous system disorders10/13
DiarrhoeaGastrointestinal disorders8/13
CoughRespiratory, thoracic and mediastinal disorders5/13
Dermatitis diaperSkin and subcutaneous tissue disorders5/13
AnaemiaBlood and lymphatic system disorders4/13
VomitingGastrointestinal disorders4/13
NasopharyngitisInfections and infestations4/13
HypotensionVascular disorders4/13
Salivary hypersecretionGastrointestinal disorders3/13

Baseline characteristics

The safety population included all participants enrolled in the study who have received any amount of study drug.

Age, Continuous
Age, Continuous(months)Eladocagene Exuparvovec
Mean45.2 ± 29.48
Sex: Female, Male
Sex: Female, Male(Participants)Eladocagene Exuparvovec
Female7
Male6
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Eladocagene Exuparvovec
Hispanic or Latino2
Not Hispanic or Latino10
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Eladocagene Exuparvovec
American Indian or Alaska Native0
Asian10
Native Hawaiian or Other Pacific Islander0
Black or African American0
White2
More than one race0
Unknown or Not Reported1
Homovanillic Acid (HVA) Metabolite Level
Homovanillic Acid (HVA) Metabolite Level(nanomoles (nmol)/liter (L))Eladocagene Exuparvovec
Mean22.54 ± 32.34
08

Study locations

6 sites
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2021 to primary completion in May 2023, 24 months.

Results were first posted in Jan 2025, 1 year 7 months after primary completion. A results delay was requested in May 2024.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2021
First posted
May 26, 2021
StartActual
May 12, 2021
Primary completionActual
May 22, 2023
CompletionEst.
Apr 30, 2028
Results delay requested
May 10, 2024
Results first posted
Jan 1, 2025
Last update
Apr 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04903288
Lead sponsor
PTC Therapeutics
Responsible party
Sponsor
First posted
May 26, 2021
Start date
May 12, 2021
Primary completion
May 22, 2023
Completion
Apr 30, 2028 (estimated)
Results posted
Jan 1, 2025
Last update
Apr 24, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion